Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM283 Alone and with Pegylated Interferon in Hepatitis C
NCT00120835Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of valopicitabine in hepatitis C (HCV), sponsored by Merck & Co.. Started Jul 2004; status: completed.
02
Drugs
valopicitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00120835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120835.